INTRODUCTION
============

Glutamate excitotoxicity has been implicated as a major pathogenic process in many neurodegenerative conditions, including AD (Alzheimer\'s disease), motor-neuron disease and following traumatic brain injury ([@B4]; [@B21]). Excitotoxicity occurs by over-stimulation of excitatory amino acid receptors, resulting in calcium influx and consequential pathological changes triggering neuronal loss ([@B7]; [@B13]; [@B52]). The response of an individual neuron to excitotoxicity is dependent on a number of factors, including the intensity and duration of the excitatory insult, and the profile of excitatory receptors or downstream signalling molecules expressed by the cell ([@B3]). Pathologically, excitotoxicity can result in apoptotic cell death that may be preceded by dendritic beading. Excitotoxicity has also been implicated in axon degeneration, and in cultured cortical neurons degeneration is preceded by neurofilament loss ([@B9]). Furthermore, excitotoxicity has been shown to result in a distal axonopathy in retinal ganglion cells ([@B43]) and cultured motor neurons ([@B25]). It is currently unknown as to how excitotoxicity results in axonal degeneration.

Neuronal glutamate receptors, the mediators of excitotoxicity, are found on postsynaptic densities where they are involved in synaptic transmission. However, immunohistochemical techniques have demonstrated the presence of glutamate receptors at numerous extrasynaptic sites including the soma, dendrites and spines (reviewed in [@B33]) and presynaptically ([@B49]). Importantly, electrophysiological techniques have also indicated that these receptors can be functional ([@B1]; [@B6]). Dendritic extrasynaptic receptors, and specifically NMDA (*N*-methyl-[d]{.smallcaps}-aspartate) receptors, have been particularly implicated in excitotoxicity ([@B44]). Current evidence supports the notion that synaptic receptor activation promotes neuroprotection through activation of survival genes and suppression of apoptotic genes, whereas extrasynaptic stimulation promotes cell death ([@B20]), although this may be due to differences in receptor subunits ([@B29]). Thus, the distribution of synaptic and extrasynaptic NMDA receptors, rather than total calcium load, influence neuronal susceptibility and responses to excitotoxicity (reviewed in [@B19]).

Although excitotoxicity is considered primarily a neuronal somatodendritic insult, glutamate toxicity has also been demonstrated to occur in white matter tracts lacking neuronal cell bodies. This type of toxicity, often associated with brain injury, ischaemia and glaucoma ([@B47]; [@B43]), has been attributed to glial cells known to express functional glutamate receptors ([@B32]; [@B31]). Oligodendrocytes are directly vulnerable to AMPA (α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid) mediated Ca^2+^ excitotoxicity resulting in demyelination and secondary axonal pathology ([@B55]; [@B5]). However, the recent identification of axonal glutamate receptor subunits within axonal internodal nanocomplexes, raises the possibility of direct axonal excitotoxicity ([@B34], [@B35]). The functional status of these receptors remains disputed; they may be involved in local regulatory mechanisms within the internodal nanocomplexes they reside in.

Investigation of the expression of glutamate receptors in different neuronal compartments and their role in excitotoxicity is difficult under standard culture conditions due to the inability to specifically target excitatory agonists. Similarly, *in vivo* investigations are complicated by the presence of glial cells. To overcome this, we have utilized microfluidic devices ([@B48]) to establish compartmented embryonic cortical neuron cultures. Such devices allow fluidic isolation of distal axons from cell bodies, thus allowing focal exposure of the axon or soma to excitotoxins. In this study, we have examined the maturation of primary mouse cortical neurons within a microfluidic device, in addition to immunocytochemical and Western blot analysis of the expression of glutamate receptor subunits in both the somal and distal axon compartments. To determine if excitotoxin-induced axon degeneration can result from somal or axonal exposure to excitotoxin, we also examined the effect of a chronic (24 and 72 h) exposure of glutamate to either the somal or axonal chamber.

MATERIALS AND METHODS
=====================

All animals experiments used were reviewed and approved by the Animal Ethics Committee of the University of Tasmania.

Primary cell culture
--------------------

Primary cortical neurons were dissected from the superficial layers of cerebral cortex of gestational day 14 embryos, obtained from pregnant C57Bl/6 mice and prepared as previously described ([@B12]; [@B24]). Cells were dissociated in 'initial' plating medium: Neurobasal medium (Gibco BRL, Life Technologies), 2% B27 supplement (Gibco BRL, Life Technologies), 10% foetal bovine serum, 0.5 mM glutamine, 25 μM glutamate and penicillin/streptomycin. Cell density and viability was assessed using a Trypan Blue dye exclusion assay, and the volume adjusted to achieve a density of 8×10^6^ cells/ml. Neurons were plated into prepared microfluidic devices (450 nm barrier grooves, Xona Microfluidics, [Figure 1A](#F1){ref-type="fig"}) as outlined below. In contrast to Campenot compartmented chambers utilizing Teflon divisions and scratched substrate to guide axonal growth, microfluidic devices are fabricated from PDMS using a photoresist template to create microchannels for axonal growth between compartments ([@B48]). Devices were attached to 22 cm^2^ glass coverslips (Livingstone), coated with 0.001% poly-[l]{.smallcaps}-lysine and incubated overnight. Microfluidics were rinsed with initial plating medium, which was removed immediately prior to addition of cells into the somal chamber. Plated neurons were incubated for 10 min to facilitate adhesion, followed by addition of initial plating medium. Cultures were incubated under standard conditions (37°C, 5% CO~2~), with the medium changed to \'subsequent\' growth medium (Neurobasal medium, 2% B27 supplement, 0.5 mM glutamine and penicillin/streptomycin), at 1 and 7 DIV (days *in vitro*).

![Schematic diagram of neuronal growth within the microfluidic culture device\
Cell bodies are restricted to the somal chamber, and axons extend into the distal axonal chamber (**A**). Arrows indicate selective glutamate treatment (yellow) of either the somal or distal axonal chamber, fluidic isolation is maintained by manipulating fluid levels (**B**). Quantification of axon degeneration following excitotoxicity was achieved by analysing axonal segments in each square of a superimposed grid (**C**); axonal morphology was scored as whole, beaded or fragmented (**D**). Scale bar = 5 μm.](an004e076f01){#F1}

Labelling of live cells in microfluidic chambers
------------------------------------------------

Not all neurons extended axons through to the distal chamber, therefore, to identify neuronal soma with isolated distal axons, the lipophilic membrane stain CM-DiI (1 μg/ml, Molecular Probes) was added to the distal axon chamber. Microfluidic isolation between the treated and untreated sides was achieved by maintaining a lower fluid volume on the treated side ([@B48]). Microfluidic devices were incubated for 4 h under standard growth conditions, followed by media change. Subsequent experimentation was performed the next day, as required.

In some experiments, neurons were transfected with a plasmid expressing GFP (green fluorescent protein; pmax GFP, Lonza) to allow morphological analysis of neuronal processes. Briefly, 800 ng plasmid DNA was applied to the somal chamber using the Lipofectamine^TM^ 2000 reagent (Invitrogen) for 6 h, under standard growth conditions, according to the manufacturer\'s instructions. This was followed by complete media change. Transfected neurons were visualized by fluorescence microscopy after 24 h.

Excitotoxicity
--------------

Excitotoxicity was initiated in mature (11 DIV) compartmented cultures (*n* = 5 repeats) by a single application of 100 μM glutamate in culture medium ([@B9]) to either the distal axon or somal chamber of the microfluidic device for 24 h ([Figure 1B](#F1){ref-type="fig"}). Microfluidic isolation was performed as above. Additional cultures were treated with 100 μM glutamate for 72 h to the axonal chamber, beginning at 10 DIV. Treated cultures were maintained under standard growth conditions for 24 or 72 h, followed by fixation.

Inhibition of caspase activity
------------------------------

The pan-caspase inhibitor Z-VAD-FMK (R&D Systems) was added to either the distal axon or somal chambers to inactivate caspase activity. Cultures were pre-incubated in 10 μM Z-VAD-FMK in culture medium for 2 h and excitotoxicity induced as described above.

Cell fixation and immunocytochemical labelling
----------------------------------------------

Cortical neuron cultures were fixed with 4% PFA (paraformaldehyde) for 30 min at room temperature, then permeabilized with 0.3% Triton X-100 for 2--5 min. For NR1 (NMDA receptor subunit 1) visualization, coverslips were fixed in ice-cold methanol for 10 min at −20°C, omitting permeabilization (note: AMPA receptor immunoreactivity was not affected by the method of fixation). This was followed by incubation with primary antibodies diluted in PBS, for 1 h at room temperature followed by 4°C overnight. Antibodies used in this study include those directed to GluR1 (1:100 Chemicon), GluR4 (1:500 Chemicon), MAP2 (microtubule-associated protein-2; 1:1000 Millipore), NF-M (1:1000 Serotec), NR1 (1:10,000 BD Pharmingen), synaptophysin (1:200 Millipore). All antibodies are commercially available and optimum concentrations were individually determined for each antibody. Species and isotype appropriate fluorescent AlexaFluor secondary antibodies (1:1000, Molecular Probes) were applied for 2 h at room temperature. The filamentous actin dye, phalloidin (1:200, AlexaFluor 488, Molecular Probes), was applied for 30 min during the secondary antibody incubation. All antibodies have been used in our previous studies ([@B24], [@B26]). No cross reactivity for the primary antibody\'s isotype or secondary antibody non-specific binding have been observed. Following antibody labelling, coverslips were stained with Nuclear Yellow (0.0001%, Sigma) to identify nuclei.

Western blot
------------

For Western blot analysis, the somal or distal axon chambers were harvested from 10 microfluidic devices (*n* = 2 repeats) in ice-cold Tris--Trion buffer (10 mM Tris, pH 7.4; 100 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1% Triton X-100; 10% glycerol; 0.1% SDS and 0.5% deoxycholate) supplemented with Complete^TM^ (protease inhibitor cocktail, Roche). Samples were separated by SDS/12.5% PAGE. Coomassie Brilliant Blue staining was also performed on a gel from each experiment. Protein gels were transferred to a PVDF membrane. Membranes were blocked overnight in 5% non-fat dried skimmed milk powder, followed by an overnight incubation in primary antibodies, including a combination of GluR1 (1:200, Chemicon), GluR2 (1:500, Chemicon), GluR3 (1:500, Chemicon) and GluR4 (1:500, Chemicon) for AMPA receptors and NR1 (1:1000, BD Pharmingen) for NMDA receptors. Membranes were washed in TBS-Tween. Species appropriate HRP (horseradish-peroxidase)-conjugated secondary antibodies (1:1000, Dako) were applied and visualized with chemilluminescent peroxidase substrate (Sigma).

Quantification of axon degeneration
-----------------------------------

Treated cultures were immunolabelled for neurofilaments and images for analysis were obtained using a Leica (DM LB2) fluorescence microscope fitted with a cooled CCD camera (Magnafire Optronics). Image acquisition and subsequent analysis was performed blinded to experimental conditions. Four ×400 images were randomly captured from each distal axon chamber. A 4×5 50 μm^2^ grid ([Figure 1C](#F1){ref-type="fig"}) was superimposed on each image using Adobe Photoshop (CS5). Axons in each square of the grid were scored as either whole, beaded (distinguishable swellings connected by sections of axon) or fragmented (disconnected swellings) ([Figure 1D](#F1){ref-type="fig"}). Overall degeneration was calculated as the sum of beaded and fragmented axons. Values were expressed as a percentage of total axons. Total values from each square were averaged for each coverslip and analysed using Student\'s *t*-test. *P*-values \<0.05 were considered significant. A minimum of five separate culture repeats were analysed. Data are represented as means±SEM.

RESULTS
=======

Developmental characteristics of compartmented cortical neuronal culture
------------------------------------------------------------------------

Mouse cortical neuron cultures were established within compartmented microfluidic culture devices ([@B48]) and their growth characteristics were examined over a time course ([Figures 2A--2E](#F2){ref-type="fig"}). Initial neuronal development (1--3 DIV) was restricted to the somal chamber ([Figure 2A](#F2){ref-type="fig"}). By 5 DIV, the neurons had extended multiple neurites within the somal chamber ([Figure 2C](#F2){ref-type="fig"}) and axons were present within the microchannels ([Figure 2D](#F2){ref-type="fig"}). At 7 DIV long, relatively unbranched axons were present extending from the microchannels into the distal axon chamber, forming an extensively branched network at 11 DIV ([Figure 2F](#F2){ref-type="fig"}). Isolated axonal health declined from 14 DIV, with extensive distal axon degeneration present at 15 DIV ([Figure 2H](#F2){ref-type="fig"}). Degeneration of axons within the distal axon chamber from 15 DIV was not accompanied by degeneration within the somal chamber ([Figure 2G](#F2){ref-type="fig"}).

![Neuronal growth in compartmented culture\
Initial neuronal growth in compartmented culture (2 DIV) (**A**) is restricted to the somal chamber with axons extending into the distal chamber to form a branched network at 11 DIV (**B**). At 5 DIV neuronal growth is characterized by branched neurites within the somal chamber (**C**) and neurites visible within the microchannels (arrow) (**D**). At 11 DIV neurites within somal chamber (**E**) were densely branched, and axons within the distal axon chamber (**F**) had formed extensive branched networks. Neurons retained normal healthy morphology within the somal chamber at 15 DIV (**G**) despite severe deterioration of isolated axons (**H**). Immunolabelling of 11 DIV neurons (**I**) demonstrates cell bodies (MAP2, green) restricted to the somal chamber and axons (NF-M, red) present within the somal chamber and extending to the distal axon chamber. Neurons (Nuclear Yellow, blue) with isolated axons were identified by CM-DiI (red) retrograde labelling from the distal axon chamber (**J**). Arrowhead indicates a neuron positive for CM-DiI uptake, arrow indicates a neuron negative for CM-DiI. Scale bars **A** = 100 μm, **B**--**D** = 50 μm, **E** = 30 μm, **F** = 50 μm.](an004e076f02){#F2}

Double immunolabelling verified that axons (NF-M immunoreactivity) were present in the distal axon chamber, with neuronal cell bodies and dendrites (MAP2 immunoreactivity) restricted to the somal chamber ([Figure 2I](#F2){ref-type="fig"}), as previously described by [@B48]. NF-M immunoreactive axons were also present in the somal chamber. Neurons with axons extending into the distal chamber were identified by incubating the distal axon chamber with CM-DiI prior to treatment. CM-DiI was taken up by the axons and transported to the cell body ([@B38]) ([Figure 2J](#F2){ref-type="fig"}). DiI retrograde labelling from the distal axon chamber indicated that approximately 30% of neurons extended axons to the distal chamber.

Neuronal maturity in compartmented cultures was determined by examining the presence of growth cones, synapses and spines. Previous investigations have demonstrated that under standard conditions, immature neurons prior to the development of synapses have numerous growth cones ([@B18]). As neurons mature, punctate synapses and mushroom-shaped spines are formed on the dendrites accompanied by the loss of growth cones ([@B24]). In the current study, the presence of growth cones in compartmented cultures was examined by phalloidin staining for filamentous actin and synaptic puncta were visualized by immunolabelling with the presynaptic marker synaptophysin in addition to the dendritic marker MAP2. Dendritic spine morphology was determined by examination of neurons transiently transfected with a GFP expression construct. In the somal chamber at 11 DIV, few growth cones were present and synaptophysin positive puncta were immunolabelled along MAP2 immunopositive dendrites ([Figure 3A](#F3){ref-type="fig"}), with the number and density of puncta varying between cells, congruent with previous investigations ([@B24]). Furthermore, GFP expression revealed short, mushroom-shaped spines ([Figure 3B](#F3){ref-type="fig"}) on the dendrites in addition to a number of long filopodial spines ([Figure 3C](#F3){ref-type="fig"}). These data indicate that, in the somal chamber, synapses were present in accordance with neuronal maturity in standard cultures ([@B24]). However, in the distal axonal chamber at this developmental stage, large growth cones were present at the ends of axons ([Figure 3D](#F3){ref-type="fig"}), indicating a stage of immaturity not usually seen in standard cultures at this time point *in vitro.*

![Markers of neuronal maturity in compartmented culture\
At 11 DIV, synaptophysin expression is localized to puncta (arrows) along MAP2 immunoreactive dendrites (**A**) within the somal chamber. GFP expression indicates short, mushroom-shaped spines (arrows) along dendrites (**B**) in addition to long filopodial spines (arrows) (**C**). Axons within the distal axon chamber (**D**) retain growth cones, immunoreactive for filamentous actin; inset shows higher power of growth cone morphology. Scale bars **A** = 25 μm, **B**--**C** = 4 μm, **D** = 20 μm.](an004e076f03){#F3}

Glutamate receptor expression in compartmented cultures
-------------------------------------------------------

To examine whether components of the machinery required for functional glutamatergic signalling, and therefore excitotoxicity, were present, the expression of glutamate receptor subunits was determined. Expression of both NMDA and AMPA receptors was examined within the somal and distal axon chambers of mature (11 DIV) cultures by immunocytochemistry using glutamate subunit specific antibodies. The expression profiles of the receptors varied between neurons within each culture. Within the somal chamber, immunoreactivity for AMPA (GluR1) and NMDA (NR1) receptor subunits was present throughout the soma, with punctate expression along the dendrites ([Figures 4A and 4B](#F4){ref-type="fig"}). Within the distal chamber, AMPA subunit labelling (GluR4) was frequently present and punctate along distal axons and within the growth cone ([Figure 4C](#F4){ref-type="fig"}). Immunoreactivity for NMDA receptors was occasionally present within distal axon growth cones ([Figure 4D](#F4){ref-type="fig"}).

![Expression of AMPA and NMDA glutamate receptor subunits in compartmented culture\
AMPA (GluR1) and NMDA (NR1) immunoreactivity were both present throughout the soma, with punctate expression along the dendrites (**A**, **B**). Distal axon AMPA (GluR4) immunoreactivity was frequently present, along distal axons and within the growth cone (**C**). Expression of NMDA receptors (NR1) was occasionally present within distal axon growth cones (**D**). Western blot analysis of somal and distal axonal expression (**E**) indicates AMPA subunits in both chambers; however, NMDA receptors were not detected in the distal axon chamber (**F**). Scale bars **A**--**B** = 20 μm, **C**--**D** = 50 μm.](an004e076f04){#F4}

To confirm the presence of glutamate receptor subunits in the somal and distal axon chambers, protein was harvested from each chamber and glutamate receptor subunit expression determined by Western blot analysis. Coomassie staining of SDS/PAGE gels demonstrated a good yield of protein from both chambers ([Figure 4E](#F4){ref-type="fig"}). Western blots confirmed the presence of NMDA (NR1 labelling at 120 kDa) and AMPA (GluR1 GluR2, GluR3 and GluR4 labelling at 100 kDa) receptors in the somal chambers ([Figure 4F](#F4){ref-type="fig"}). Interestingly, Western blot analysis also demonstrated the presence of AMPA receptors in protein harvested from the distal axon chamber ([Figure 4F](#F4){ref-type="fig"}). NMDA receptors, however, were not detected in the distal axon chamber ([Figure 4F](#F4){ref-type="fig"}). Together, these data indicate differential expression of glutamate receptors subunits on both the somatodendritic compartment and distal axon of the cortical neuron, with strong evidence for the presence of AMPA receptor subunits in the axon.

Functional contribution of expressed glutamate receptors to focal excitotoxicity
--------------------------------------------------------------------------------

To determine the role of the axon in mediating excitotoxicity, mature (11 DIV) mouse cortical neurons were treated with 100 μM glutamic acid or vehicle control, applied to either the somal or the distal axon chamber of the microfluidic device, and maintained for 24 h post-treatment. Following treatment, distal axon degeneration was assessed based on neurofilament immunoreactivity for axonal integrity.

Glutamate applied to the somal chamber resulted in extensive neuronal degeneration, both within the treated chamber and at the unexposed distal axon. Specifically, axons in both chambers frequently showed a beaded morphology and additionally complete axon fragmentation was present in some axons. Quantitative analysis of neurofilament immunoreactivity in the untreated distal axon chamber demonstrated that somal glutamate treatment resulted in a significant (*P*\<0.01) 3-fold increase in total axon degeneration, including the sum of both beaded and fragmented axons (80.5%±2.9). Beading (32.2%±2.4) and fragmentation (49.5%±3.3) were significantly (*P*\<0.01) increased relative to untreated controls (26.9%±2.8 total damage; 13.5%±1.7 beading; 14.3%±1.5 fragmentation) ([Figure 5A](#F5){ref-type="fig"}). Widespread axonal degeneration was also present in the treated somal chamber (not quantified) ([@B9]).

![Axon degeneration following excitotoxicity\
Somatodendritic excitotoxicity resulted in a significant (*P*\<0.01) 3-fold increase in distal axon degeneration (**A**). Distal axonal excitotoxicity resulted in a significant (*P*\<0.01) 1.5-fold increase in distal axon degeneration (**A**). Immunocytochemical analysis of control and treated cultures (**B--J**). Distal axons demonstrated increased beading and fragmentation between control (**B**), somal-treated (**C**) and distal axon-treated (**D**) cultures, visualized with NF-M immunoreactivity. Arrows indicate whole axons, arrowheads indicate fragmented and beaded axons. Within the somal chamber, MAP2 immunoreactive dendrites demonstrated increased beading between control (**E**) and somal-treated (**F**) cultures. Distal axon-treated cultures (**G**) did not demonstrate changes to dendritic morphology. Arrows indicate soma, arrowheads indicate dendrites. Similarly, nuclear health (Nuclear Yellow) declined between control (**H**) and somal-treated cultures (**I**) as demonstrated by an increase in apoptotic nuclei (arrowhead) versus normal nuclei (arrow). Distal axon-treated cultures (**J**) showed no change in nuclear morphology compared with controls. Scale bar = 50 μm.](an004e076f05){#F5}

We next determined if specific targeting of excitotoxicity to the distal axon chamber could also result in degenerative changes. Twenty-four hour glutamate exposure also resulted in beading and fragmentation of the distal axon. Quantitative analysis of neurofilament immunoreactivity demonstrated a significant (*P*\<0.01) 1.5-fold increase in total degeneration (46.7%±3.2), axonal beading (21.3%±1.0) and axonal fragmentation (25.5%±2.3) when compared with untreated controls (26.9%±2.8, total damage; 13.5%±1.7 beading; 14.3%±1.5 fragmentation) ([Figure 5A](#F5){ref-type="fig"}). The degenerative changes in distally treated cultures was significantly (*P*\<0.01) 1.5-fold less than the distal degeneration recorded from somal treatment, assessed as both axonal beading and fragmentation.

The neuron-wide effects of somal and axonal excitotoxin exposure were examined to determine the extent of neuronal damage. In addition to distal axon morphology (neurofilament immunoreactivity) ([Figures 5B--5D](#F5){ref-type="fig"}), we examined changes to dendrites (MAP2 immunoreactivity) ([Figures 5E--5G](#F5){ref-type="fig"}) and overall cell health, using Nuclear Yellow to assess nuclear integrity ([Figures 5H--5J](#F5){ref-type="fig"}). Somal excitotoxicity resulted in severe dendritic beading at 24 h post-treatment ([Figure 5E](#F5){ref-type="fig"}), as has been described previously ([@B36]). There was a significant (20%±3.2, *P*\<0.01) increase in apoptotic (condensed) nuclei following somatodendritic excitotoxicity ([Figure 5I](#F5){ref-type="fig"}). In contrast with somal exposure, the unexposed somal chambers of distally treated cultures had no change to dendritic morphology relative to controls ([Figure 5G](#F5){ref-type="fig"}). The nuclear morphology of CM-DiI-stained neurons was assessed; however, there was no difference in the percentage of apoptotic nuclei between axonal excitotoxicity at 24 h and untreated controls (25.4%±2.0 24 h excitotoxicity; 22.7%±1.3 control).

To investigate whether delayed apoptosis occurred, through dying-back from the axon, cultures were treated with 100 μM glutamate to the distal axon chamber for 72 h at 10 DIV and axon degeneration and cell death assessed. Seventy two hour-treated cultures demonstrated a significant (*P*\<0.01) increase in total axon degeneration from untreated controls (52.5%±4.3 and 32.5%±2.6, respectively); however this was not significantly (*P*\>0.05) different to cultures treated for 24 h (46.7%±3.2) ([Figure 6A](#F6){ref-type="fig"}). Additional cultures were labelled with CM-DiI to the distal axon chamber prior to treatment to specifically label neuronal soma with axons in the distal chamber. Following treatment, the nuclear morphology of DiI positive soma was assessed with no significant (*P*\>0.05) change to the percentage of apoptotic nuclei relative to controls (13.9%±1.9 72 h glutamate, 17.8%±1.4 controls) ([Figure 6B](#F6){ref-type="fig"}).

![Cell effects of long-term distal axonal excitotoxicity\
Application of glutamate to the distal axon compartment for 72 h significantly (*P*\<0.01) increased percentage axon degeneration from untreated controls, however, it did not significantly (*P*\>0.05) alter the percentage of axon degeneration from 24 h treated cultures (**A**). Application of glutamate to the distal axon chamber for 72 h did not significantly (*P*\>0.05) alter the percentage of apoptotic nuclei between untreated, 24 h and 72 h treated cultures (**B**).](an004e076f06){#F6}

Mechanisms of focal excitotoxin-induced axonal degeneration
-----------------------------------------------------------

To investigate whether axon degeneration following soma or axonal excitotoxicity involved activation of caspases and apoptotic pathways, 11 DIV cultures were pre-incubated with 10 μM Z-VAD-FMK pan caspase inhibitor to either the somal or distal axon chambers. Cultures were subsequently treated with 100 μM glutamate for 24 h to induce excitotoxicity in the two compartments. The efficacy of the inhibitor was confirmed by a significant (*P*\<0.05) decrease in apoptotic nuclei following somal excitotoxicity when compared with no inhibitor (16.06%±3.93 glutamate only; 3.93%±3.15 inhibition+glutamate).

Somal caspase inhibition prior to somal excitotoxicity significantly (*P*\<0.01) decreased distal axon degeneration (31.3%±3.2) when compared with somal treatment alone (54.5%±2.3) ([Figure 7A](#F7){ref-type="fig"}). Axonal caspase inhibition combined with somal excitotoxicity also significantly (*P*\<0.01) reduced axon degeneration (36.4%±2.1) ([Figure 7A](#F7){ref-type="fig"}). Somal caspase inhibition and axonal caspase inhibition similarly significantly (*P*\<0.01) decreased axon degeneration in conjunction with axonal excitotoxicity (2.5%±4.0 and 9.9%±2.4, respectively) compared with axonal excitotoxicity alone (20.6%±3.2) ([Figure 7B](#F7){ref-type="fig"}). For both axonal and somal excitotoxicity, there was no significant (*P*\>0.05) difference between somal and axonal application of caspase inhibition.

![Mechanisms of axon degeneration following focal excitotoxicity\
Inhibition of caspase activity, in either the somal or the axonal chamber, significantly (*P*\<0.01) decreased axon degeneration following somal excitotoxicity (**A**), and following axonal excitotoxicity (**B**). Results expressed relative to untreated controls.](an004e076f07){#F7}

DISCUSSION
==========

In this study, we have grown primary cortical neurons in a compartmentalized microfluidic device to determine the expression of glutamate receptors in specific neuronal compartments and to investigate degenerative responses following chronic targeted distal axon excitotoxicity. Of relevance to the current study, our previous investigations ([@B24]), and those of others ([@B8]; [@B28]) have demonstrated that neuronal vulnerability to excitotoxicity is dependent on neuronal maturity and expression of glutamate receptor subunits, which is variable between cell types. Thus, for the current study it was important to determine the maturity of neurons within the microfluidic culture chambers.

Under standard growth conditions, development of primary murine cortical neurons occurs via a sequence of predetermined steps that include neurite outgrowth, polarization and elongation followed by movement of glutamate receptors into the synapses and loss of immaturity markers such as growth cones ([@B14], [@B18]). The timing of these developmental stages is dependent on culture density ([@B10]; [@B42]). Assessment of neuronal growth of cultures in microfluidic chambers indicates that development occurs in a similar manner to standard cortical culture within the somal chamber, including the presence of mature spines and punctate glutamate receptor subunits at 11 DIV. However, in the axonal chamber, even at relative culture maturity (11 DIV), numerous axonal growth cones remained present. The presence of growth cones is likely to be due to the inability of presynaptic neurons to find postsynaptic partners in this culture system and may affect the axonal expression of glutamate receptor subunits.

Our data indicate that, in addition to the well-documented expression of glutamate receptor subunits on the somatodendritic compartment of cultured primary cortical neurons ([@B24]), glutamate receptors, and in particular AMPA receptors, were also present on axons. Excitotoxic stimulation of axonal glutamate receptors resulted in axonal degeneration, which, unlike somatodendritic exposure, was confined to the exposed segment of the axon and did not cause retrograde degeneration or apoptotic cell death, even at extended time-points of 72 h. These data also suggest the presence of functional glutamate receptor complexes on the axons in this chamber.

Axon degeneration and excitotoxicity
------------------------------------

Axon degeneration following glutamate receptor stimulation has been previously reported in a number of studies. *In vitro* studies have indicated that axon degeneration occurs as a result of chronic excitotoxicity in cultured motor ([@B25]) and cortical ([@B9]) neurons. In these studies, however, glutamate or other agonists were globally applied to the cells and so it is unclear if axon degeneration occurred from toxicity to somatodendritic glutamate receptors, or receptors present on axons, growth cones or presynaptic terminals. *In vivo* studies have allowed focal excitotoxin exposure of neuronal compartments. Somal glutamate exposure to retinal ganglion cells resulted in a degeneration of the distal axon ([@B43]), confirming excitotoxic axonal degeneration in the unexposed axon segment, consistent with the current study in cortical neurons. *In vivo* glutamate exposure to myelinated axons also resulted in axonal damage to the optic nerve ([@B30]) and external capsule ([@B15]). The vulnerability of myelinating oligodendrocytes to excitotoxicity has been well documented and myelin has been demonstrated to play a role in axonal excitotoxicity ([@B16]). However, studies using myelin-deficient Shiverer mice show that compact myelin is not required for AMPA toxicity to axons ([@B41]).

A study by [@B50] utilized a Campenot style compartmentalized culture system to directly examine the role of glutamate receptor activation in axon degeneration in the absence of glial cells. Their data demonstrated that brief (2 h) axonal exposure to glutamate receptor agonists, NMDA or AMPA, did not result in significant axonal degeneration. Conversely, the current study using a compartmentalized microfluidic culture system, demonstrates the novel finding that chronic (24 h) glutamate exposure results in axonal blebbing and fragmentation in a proportion of axons. The reasons for these conflicting results may be the length of time of the exposure, the agonists used or differences in the culture systems, which may select for isolation of axons from specific cell types. Interestingly, *in vivo* studies also suggest difference in chronic versus acute excitotoxic axonal exposure ([@B30]). These data suggest that excitotoxicity can be mediated through glutamate receptors expressed on the axon.

Excitotoxicity and glutamate receptor expression
------------------------------------------------

In the current study excitotoxicity could be mediated through glutamate receptors expressed either on the axon shaft or on the growth cones. Glutamate receptors can be trafficked to the axonal compartment and in particular their presence within growth cones during neuronal development has been well documented ([@B24]), with a proposed involvement in pathfinding ([@B56]). Recently, subunits for AMPA and kainate receptors have been shown to be present on myelinated axons ([@B34], [@B35]), although the functional activity of these receptors is currently disputed. Our data confirm the presence of AMPA receptors in the axonal compartment of cultured axons by immunocytochemical labelling and Western blot analysis. The role of these axonal glutamate receptors is unclear; however, the expression of functional NMDA and non-NMDA receptors on glial cells ([@B17]; [@B54]) raises the possibility that axonal glutamate receptor subunits may facilitate glutamatergic signalling between axons and myelinating oligodendrocytes or astrocytes.

A limitation of the current study is that cultured distal axons were unable to synapse on other neurons, preventing the formation of the presynaptic terminal. This excludes the possibility that excitotoxicity was mediated through presynaptic receptors. *In vivo*, both NMDA and AMPA receptors are found presynaptically, where they are thought to regulate glutamate release (recently reviewed in [@B39]) and could potentially be targets for excitotoxic stimulation. Although the expression pattern of axonal glutamate receptors may differ *in vivo*, the current study suggests that excitotoxicity can be mediated through extrasynaptic glutamate receptors expressed on the axon.

The demonstration of the extrasynaptic expression of glutamate receptor subtypes ([@B37]; [@B49]; [@B23]; [@B53]) suggests a wider role for glutamate than solely as an inter-neuronal excitatory transmitter ([@B2]). Glutamate receptor subunits at non-synaptic sites on dendrites and spines are thought to act as a reserve supply of synaptic receptors (for recent review see [@B33]). However, electrophysiological recordings indicate that these extrasynaptic receptors are functional ([@B1]) and a modulatory role has been suggested, through activation by glutamate spillover from the synapse or glial derived glutamate ([@B11]; [@B22]). In terms of pathological stimulation of glutamate receptors, extrasynaptic and synaptic receptors have been reported to play a significantly different role in excitotoxicity. Stimulation of synaptic NMDA receptors is neuroprotective, whereas activation of extrasynaptic NMDA receptors triggers neuronal degeneration ([@B20]), although some authors demonstrate that preferential expression of receptor subunit types at extrasynaptic sites is responsible for this effect rather than localization itself ([@B29]).

Mechanisms of axonal glutamate excitotoxicity and implications for disease
--------------------------------------------------------------------------

Mechanism of axonal degeneration, including potential differences between axonal and somal glutamate stimulation, cannot be fully determined in the current study; however, the protective effect of a pan-caspase inhibitor suggests the involvement of pathways associated with apoptosis. It is of particular interest to note that application of inhibitors to either the soma or axon provided protection from degeneration. The role of axonal caspases in axonal degeneration is being increasingly recognized and has been reported in a number of models ([@B45], [@B46]). The study also suggests that retrograde signalling to the soma is involved in axon degeneration following axonal excitotoxicity, without inducing frank apoptosis. Further elucidating the mechanisms of excitotoxin-induced axon degeneration will be the subject of future studies using this model.

The findings of the current study have a number of implications for our understanding of neurodegenerative disease. Excitotoxicity within the white matter has been shown to occur in a number of degenerative conditions including glaucoma ([@B43]) and multiple sclerosis ([@B40]), and is also common following injury (reviewed in [@B27]). Furthermore, axonal excitotoxicity may be involved in any condition involving excitotoxic pathogenesis including, potentially, ALS (amyotrophic lateral sclerosis) ([@B51]) and AD ([@B21]), with local regions of excitotoxicity triggering axon degeneration and synaptic loss. At present, excitotoxic damage is attributed to neuronal soma and glial cells, and secondary axon degeneration via axon--glia signalling. The current study suggests that axon degeneration could occur from direct exposure of the axon to excitotoxins. However, axonal excitotoxicty did not result in a dying back, even 72 h following exposure. The relative immaturity of the axons through lack of presynaptic targets and therefore retrograde signals from postsynaptic cells may be a factor in the lack of die back in this study. It is currently unknown as to how axonally mediated excitotoxicity affects a cell\'s survival in mature cells *in vivo* in the long-term. However, this may have therapeutic implications as intervention may need to be directed specifically to induce axon protection.
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